Total Payments
$59,166
2024 Payments
$859.17
Companies
2
Transactions
153
Payment Breakdown by Category
Consulting$56,214 (95.0%)
Other$2,050 (3.5%)
Travel$601.32 (1.0%)
Food & Beverage$300.00 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $56,214 | 134 | 95.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,200 | 2 | 2.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $850.00 | 1 | 1.4% |
| Travel and Lodging | $601.32 | 14 | 1.0% |
| Food and Beverage | $300.00 | 2 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $58,866 | 151 | $0 (2024) |
| Allergan Inc. | $300.00 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $859.17 | 2 | Novartis Pharmaceuticals Corporation ($859.17) |
| 2023 | $1,642 | 4 | NOVARTIS PHARMACEUTICALS CORPORATION ($1,642) |
| 2022 | $759.38 | 2 | Novartis Pharmaceuticals Corporation ($759.38) |
| 2021 | $2,560 | 8 | Novartis Pharmaceuticals Corporation ($2,560) |
| 2020 | $10,245 | 35 | Novartis Pharmaceuticals Corporation ($10,245) |
| 2019 | $1,200 | 2 | Novartis Pharmaceuticals Corporation ($1,200) |
| 2018 | $34,450 | 77 | Novartis Pharmaceuticals Corporation ($34,150) |
| 2017 | $7,450 | 23 | Novartis Pharmaceuticals Corporation ($7,450) |
All Payment Transactions
153 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/05/2024 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $850.00 | General |
| Category: Neurology | ||||||
| 01/05/2024 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Travel and Lodging | In-kind items and services | $9.17 | General |
| Category: Neurology | ||||||
| 05/01/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Neurology | ||||||
| 05/01/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | MAYZENT (Drug) | Travel and Lodging | In-kind items and services | $6.55 | General |
| Category: Neurology | ||||||
| 01/03/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Neurology | ||||||
| 01/03/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | MAYZENT (Drug) | Travel and Lodging | In-kind items and services | $135.60 | General |
| Category: Neurology | ||||||
| 11/02/2022 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2022 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $9.38 | General |
| Category: NEUROSCIENCE | ||||||
| 10/25/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/25/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $40.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/14/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/14/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $40.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/11/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/11/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $40.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/18/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/18/2021 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $40.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/28/2020 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/28/2020 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $220.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/28/2020 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $40.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2020 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2020 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2020 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $40.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2020 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2020 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $40.00 | General |
| Category: NEUROSCIENCE | ||||||
| 08/31/2020 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: NEUROSCIENCE | ||||||
About Dr. Arvin Chin, MD
Dr. Arvin Chin, MD is a Critical Care Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255373205.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Arvin Chin, MD has received a total of $59,166 in payments from pharmaceutical and medical device companies, with $859.17 received in 2024. These payments were reported across 153 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($56,214).
Ad
Practice Information
- Specialty Critical Care Medicine
- Location New York, NY
- Active Since 06/12/2006
- Last Updated 07/08/2007
- Taxonomy Code 207LC0200X
- Entity Type Individual
- NPI Number 1255373205
Products in Payments
- GILENYA (Drug) $48,075
- MAYZENT (Drug) $10,791
- VRAYLAR (Drug) $150.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in New York
Dr. Lonny Yarmus, D.o, D.O
Critical Care Medicine — Payments: $1.0M
Critical Care Medicine $1.0M
Dr. Charles Powell, M.d, M.D
Critical Care Medicine — Payments: $611,991
Critical Care Medicine $611,991
Michael Niederman, Md, MD
Critical Care Medicine — Payments: $230,582
Critical Care Medicine $230,582
Maria Padilla, Md, MD
Critical Care Medicine — Payments: $135,278
Critical Care Medicine $135,278
Dr. Ani Nalbandian, M.d, M.D
Critical Care Medicine — Payments: $100,000
Critical Care Medicine $100,000
Dr. James Horowitz, M.d, M.D
Critical Care Medicine — Payments: $87,935
Critical Care Medicine $87,935